control group:Gefitinib

4 trials

Sponsors

Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Chengdu Fifth People's Hospital, Affiliated hospital of Jiangsu University

Conditions

EGFR mutation-positive advanced NSCLCNon-small cell lung cancerlung cancer

Early Phase 1

Clinical study of Fei-Yan-Ning Granule delaying EGFR-targeted drug resistance for lung cancer

Active, not recruitingChiCTR2000036728

Longhua Hospital, Shanghai University of Traditional Chinese Medicinelung cancer

Start: 2020-10-01Updated: 2020-09-21

Clinical study of Fei-Yan-Ning Granule delaying EGFR-targeted drug resistance for lung cancer

Active, not recruitingITMCTR2000003679

Longhua Hospital, Shanghai University of Traditional Chinese Medicinelung cancer

Start: 2020-10-01Updated: 2023-02-20

Phase 2

Phase I/II Trails of NKT Cell in Combination With Gefitinib For Non Small Cell Lung Cancer

Active, not recruitingChiCTR-IIR-17013471

Affiliated hospital of Jiangsu UniversityNon-small cell lung cancer

Start: 2017-12-01Updated: 2017-11-27

Phase 4

Clinical study of gefitinib combined with recombinant human endostatin or gefitinib in the first-line treatment of EGFR mutation positive advanced NSCLC

RecruitingChiCTR2000039905

Chengdu Fifth People's HospitalEGFR mutation-positive advanced NSCLC

Start: 2020-11-02Updated: 2021-02-22

Related Papers

A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.

2021-07-3116 citations